Kenai Therapeutics
PrivateLast Round
Grant
Jan 5, 2026
Total Funding Raised
$97M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Kenai Therapeutics operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Grant round in January 2026.
Kenai Therapeutics is a biotechnology company that develops off-the-shelf neuron replacement therapies for neurological disorders such as Parkinson's disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Kenai Therapeutics Comparables
Compare Kenai Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BrainXell Therapeutics | 88% | |
| Aspen Neuroscience | 86% | |
| iRegene Therapeutics | 85% |
For institutional investors. Book with your work email.
Kenai Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jan 5, 2026 | ||||
| Series A | Feb 29, 2024 | ||||
| Grant | Feb 14, 2023 | ||||
| Seed | Jul 19, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Kenai Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series A |
| Saisei Ventures | Series A, Seed |
| The Chernin Group | Series A |
| California Institute for Regenerative Medicine | Grant |
| Cure Ventures | Series A |
| Euclidean Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 12, 2026
Allen Waldrop appointed to the Board of Directors.
- Feb 24, 2026
Blake Arnold appointed as new Chief Business Officer.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresAug 18, 2026
Kenai Therapeutics, Inc. appoints Mark J. Gergen, J.D., to its board of directors in California on Aug 18th '26, adding his more than three decades of life sciences operating and transaction experience as it advances RNDP-001 through clinical development for Parkinson's disease.
For institutional investors. Book with your work email.
Kenai Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Kenai Therapeutics's valuation, stock price, and market status.
Is Kenai Therapeutics a public or private company?
Kenai Therapeutics is a private company.
What is the current stock price of Kenai Therapeutics?
Kenai Therapeutics is a private company, so its shares have no public market price. Caplight tracks Kenai Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Kenai Therapeutics worth (valuation)?
Valuation information for Kenai Therapeutics is not publicly available.
Can I buy Kenai Therapeutics stock?
Kenai Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Kenai Therapeutics's last funding round?
Kenai Therapeutics's most recent funding round was Grant on January 5, 2026.
Who are the main investors in Kenai Therapeutics?
Key investors in Kenai Therapeutics include The Column Group, Saisei Ventures, The Chernin Group, Cure Ventures.
Will Kenai Therapeutics IPO soon?
No public IPO plans have been announced for Kenai Therapeutics.
How can I track Kenai Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Kenai Therapeutics's shares on secondary markets.